AI assistant
Sending…
ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2023
Jan 12, 2023
31071_dirs_2023-01-11_e1c28068-7b02-4062-b71e-df33249c9972.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2023-01-10
Reporting Person: GIVEN DOUGLAS B (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-01-10 | Common Stock | A | 7867 | $0.00 | Acquired | 124135 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-01-10 | Common Stock | $33.03 | A | 4593 | Acquired | 2033-01-10 | Common Stock (4593) | Direct |
Footnotes
F1: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.
F2: Represents options, which will vest in one installment on the first anniversary of the grant date.
More from ARROWHEAD PHARMACEUTICALS, INC.
Regulatory Filings
2026
May 7
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
May 6
Major Shareholding Notification
2026
Apr 29
Major Shareholding Notification
2026
Apr 28
Major Shareholding Notification
2026
Apr 24
Major Shareholding Notification
2026
Mar 26
Regulatory Filings
2026
Mar 20
Interim / Quarterly Report
2026
Feb 5